Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Arch Surg. 2011 Oct;146(10):1204-9. doi: 10.1001/archsurg.2011.239.

Lung transplant in idiopathic pulmonary fibrosis.

Author information

  • 1Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.

Abstract

OBJECTIVE:

To review the present status of lung transplant (LTx) in patients with idiopathic pulmonary fibrosis (IPF).

DATA SOURCES:

Current English-language literature review using MEDLINE.

STUDY SELECTION:

Prospective and retrospective trials, series, reviews, databases, and editorials regarding the clinical and basic science aspects of LTx in patients with IPF.

DATA EXTRACTION:

We analyzed results from trials and series.

DATA SYNTHESIS:

Idiopathic pulmonary fibrosis is an incurable disease with a dismal prognosis. The only treatment of proven benefit is LTx. Since the introduction of the Lung Allocation Score, IPF has become the most common indication for LTx in the United States. These patients have a limited life expectancy and benefit from early referral for transplant. Although controversial, the most recent data suggest that bilateral LTx is superior to single LTx in the population of patients with IPF. For this population, LTx increases the length and quality of their lives.

CONCLUSION:

Although patients with IPF have a dismal prognosis, LTx is a safe and effective treatment to improve their survival and functional status.

Comment in

PMID:
22006881
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk